Novartis
VC Fund
Basel, Switzerland
Novartis is a global healthcare company based in Switzerland that provides solutions to address the evolving needs of patients worldwide.
- Total investments:
- 88
- Last investment:
- Lead investor:
- 23%
Last updated:
For AI agents: llms.txt
Industries Novartis invests in
Stages Novartis invests in
Countries Novartis invests in
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
| See all 21 contacts → | |||
Investment Focus
Industry
- Health Care 40 (45%)
- Biotechnology 40 (45%)
- Therapeutics 20 (23%)
- Medical 17 (19%)
- Pharmaceutical 11 (13%)
Stage
- Series A 20 (23%)
- Series B 18 (20%)
- Series C 11 (13%)
- Venture - Series Unknown 9 (10%)
- Grant 5 (6%)
Country
- United States 43 (49%)
- Switzerland 4 (5%)
- Canada 3 (3%)
- United Kingdom 3 (3%)
- China 2 (2%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
Enrico Vanni
Board of Directors
|
Board of Directors | Total investments: 0 | Find email | |
Iya Khalil
Global Head of the AI Innovation Center at Novartis
|
Global Head of the AI Innovation Center at Novartis | Total investments: 0 | Find email | |
José Marcilla
Senior Vice President Head of Southern, Eastern, Russia & Central Europe
|
Senior Vice President Head of Southern, Eastern, Russia & Central Europe | Total investments: 1 | Find email | |
Justin Rauschkolb
Associate Director, Digital Marketing - HCP Media
|
Associate Director, Digital Marketing - HCP Media | Total investments: 0 | Find email | |
Rana Lonnen
Managing Director
|
Managing Director | Total investments: 12 | Find email | |
| See all 21 team members → | ||||
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| Flare Therapeutics is a biotechnology company opening up a new therapeutic space with a novel approach to decipher the biology of transcription factors to develop small molecule medicines. Based on insights from the seminal work of its scientific founders, Flare’s team has uncovered ‘switch sites,’ druggable regions that are key targets fortranscription factor regulation to address mutations that cause disease. Its drug discovery to target switch sites has rapidly advanced, resulting in an emerging pipeline of drug programs that address well-validated transcription factors, initially focused on precision oncology with future potential in neurology, rare genetic disorders, immunology, and inflammation. | $85M / Series C / Jun 30, 2026 | ||
| Relation Therapeutics is a biotechnology company that focuses on humanizing drug discovery and development. It leverages human genetics and clinical omics data and utilizes patient-derived tissue samples with functional genomics interventional experiments to identify, validate, and prosecute therapeutic programs. | $26M / Venture - Series Unknown / Dec 09, 2025 | ||
| Octave Bioscience is an early-stage molecular diagnostics company focused on neurodegenerative diseases and conditions. The company was co-founded by Melinda Thomas and William Hagstrom in 2013. Octave Bioscience is headquartered in Menlo Park, California, United States. | $35.6M / Series C / Sep 04, 2025 | ||
| Borealis Biosciences is a company in the field of next-generation RNA medicines, specializing in molecular and cellular biology, vivarium space, chemistry, and analytical capabilities. | $150M / Series A / Aug 22, 2024 | ||
| Dren Bio is a biotechnology company with a portfolio of attractive projects focused on powerful protein engineering technologies for the depletion of cells, protein aggregates, and other disease-causing agents. It is a holding company business model aimed at creating value with multiple projects as stand-alone assets. | $25M / Corporate Round / Jul 24, 2024 | ||
| Catalym develops antibodies against a placental factor which is overexpressed by various tumour types. | $150M / Series D / Jul 16, 2024 | ||
| Yseop is an artificial intelligence enterprise software on the market, which automatically writes (or speaks) in intelligent and non-repetitive text, both in English and a variety of other languages, just like a human being, but at a speed of over a thousand pages per second. Using a patented enterprise software based on Artificial Intelligenceand Natural Language Generation, Yseop boosts the performance of business teams by automating tasks such as lead generation, up-selling, cross-selling as well as by writing prep-to-meeting reports, post meeting summaries, personalized proposals, and customer intelligence executive summaries.Yseop’s solution dramatically reduces the cost of sales and makes sales and marketing teams more efficient. With Yseop, a company’s sales team can spend more time on customer interactions and less time on administrative tasks in order to close business faster.Yseop is able to deliver its technology as a SaaS or as an annual term license hosted on a company’s servers. Currently, Yseop is able to generate text in English, German, Dutch, French, Spanish, Japanese. | Venture - Series Unknown / Dec 05, 2023 | ||
Northern Yiheng
|
Northern Yiheng is a producer of composite insulation materials made of semiconductor graphite fiber. | Series B / Sep 25, 2023 | |
| Octave Bioscience is an early-stage molecular diagnostics company focused on neurodegenerative diseases and conditions. The company was co-founded by Melinda Thomas and William Hagstrom in 2013. Octave Bioscience is headquartered in Menlo Park, California, United States. | $30M / Series B / Jul 26, 2023 | ||
| Medtech Africa is a Nigerian-based startup leveraging Artificial Intelligence and Apps to enable Cardiologists to treat and manage patients living with Cardiovascular Disease using the Patient's own data.The App, Forcardio, is a smart mobile & web application that seamlessly connects FDA-approved Bluetooth-enabled Cardiovascular devicesused by Patients through a mobile app to physician's tablet/device.Forcardio, eliminates the need for Cardiologists to use hundreds of apps to manage CVD. Forcardio App connects all CVD devices.We provide features such as AI analytics and Planning tools for Patient data for Cardiologist, emergency warning systems, on-demand video/voice call and management tools for CVD Patients. | $125K / Grant / Jun 20, 2023 | ||
| See all 88 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
FAQ
What does Novartis invest in?
Novartis invests primarily in Health Care, Biotechnology and Therapeutics startups, most often at Series A and Series B stage. Most of the 88 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Novartis?
Public channels for Novartis include LinkedIn, X (Twitter) and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Novartis?
The team at Novartis includes Enrico Vanni (Board of Directors), Iya Khalil (Global Head of the AI Innovation Center at Novartis) and José Marcilla (Senior Vice President Head of Southern, Eastern, Russia & Central Europe), among 21 team members tracked by Shizune. The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Oct 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
